Salarius Pharmaceuticals (SLRX)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.12%)
Updated Apr 17, 2024 03:51 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
SLRX 0.51 +0.01(2.12%)
Will SLRX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SLRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLRX
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
SLRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SLRX
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Wednesday's Intraday Session
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Monday's Pre-Market Session
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket